Breaking News Instant updates and real-time market news.

PCRX

Pacira

$33.30

3.8 (12.88%)

06:58
04/09/18
04/09
06:58
04/09/18
06:58

Pacira nerve block approval a 'clear positive,' at JPMorgan

In a research note partially titled "Something's Better Than Nothing," JPMorgan analyst Chris Schott says Friday night's FDA approval for nerve block is a "clear positive" for Pacira Pharmaceuticals. He notes that the Street broadly expected a Complete Response Letter for Exparel in this indication. While the approval does not include a broad nerve block label, it does allow Pacira to target 1M shoulder blocks performed annually, Schott tells investors. However, the Exparel label update also included several failed nerve block studies that should limit off label use of the drug, the analyst adds. He keeps a Neutral rating on Pacira.

  • 16

    Apr

  • 08

    May

PCRX Pacira
$33.30

3.8 (12.88%)

03/20/18
GHSC
03/20/18
NO CHANGE
Target $42
GHSC
Buy
Pacira price target lowered to $42 after Heron data at Seaport Global
Seaport Global analyst Corey Davis noted that Heron Therapeutics (HRTX) reported positive results from its two Phase 3 studies of HTX-011 for postoperative pain in bunionectomy and herniorrhaphy. While Heron's HTX-011 data suggest some competition in 2020 for Pacira's (PCRX) Exparel, Davis said dose and volume "present problems" and that Heron "may run into a pricing problem" as well. He reiterates his Buy rating on Pacira shares, though he lowered his price target on the stock to $42 from $50, noting that he has formally removed nerve block revenue for Exparel entirely from his model after the negative FDA AdCom last month.
03/21/18
JEFF
03/21/18
NO CHANGE
Target $49
JEFF
Buy
Pacira shares could be positioned for rebound, says Jefferies
Jefferies analyst David Steinberg believes shares of Pacira Pharmaceuticals could be positioned for a rebound after Symphony Health data indicated Exparel posted "well above trend growth" in February. Sales were $24M, up 3.4% from last month and up 12.6% year-over-year, according to Symphony. The data have shown double digit year-over-years gains in four of the past five months, versus just one of nine months prior, Steinberg tells investors in a research note. He believes Pacira is attractively valued at current levels and keeps a Buy rating on the shares with a $49 price target.
04/06/18
WEDB
04/06/18
NO CHANGE
Target $72
WEDB
Outperform
Wedbush says FDA response for Pacira's EXPAREL in nerve block due
Wedbush analyst Liana Moussatos reiterated an Outperform rating and $72 price target on Pacira Pharmaeuticals ahead of the expected PDUFA date for potential expansion of EXPAREL's label to specify nerve block. In a research note to investors, the analyst said she is "hopeful" that EXPAREL could potentially be used to provide improved outcomes in long-acting regional analgesia compared to infusion pumps or opioids. Whether required post-approval or in preparation for future regulatory review, she sees Pacira to continuing to evaluate EXPAREL in different nerve block techniques.
04/09/18
PIPR
04/09/18
NO CHANGE
Target $44
PIPR
Overweight
Piper reiterates Overweight on Pacira after 'watershed' nerve block approval
FDA approval of Pacira Pharmaceuticals' (PCRX) Exparel as a brachial plexus block "is something of a watershed" in that the agency has never before approved any local or regional anesthetic for a single, specific setting, Piper Jaffray analyst David Amsellem tells investors in a research note. He believes the approval suggests an increasingly aggressive FDA approach towards the opioid crisis. Amsellem points out, however, that feedback from his surgeon survey suggests a "strong degree of enthusiasm" for Heron Therapeutics' (HTRX) HTX-011. However, the feedback also indicates that non-opioid, post-operative pain space is not a zero-sum game, the analyst writes. He believes Exparel can grow "even amid greater competition." Amsellem reiterates an Overweight rating on Pacira with a $44 price target.

TODAY'S FREE FLY STORIES

KBR

KBR

$17.09

-0.06 (-0.35%)

06:04
04/19/18
04/19
06:04
04/19/18
06:04
Hot Stocks
KBR acquires Carillion's interests in Aspire Defence joint venture »

KBR announced, following…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 14

    Jun

  • 25

    Jun

GTLS

Chart Industries

$60.57

-0.22 (-0.36%)

06:03
04/19/18
04/19
06:03
04/19/18
06:03
Earnings
Chart Industries reports Q1 adjusted EPS 23c, consensus 19c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Apr

  • 17

    May

  • 29

    May

  • 29

    Aug

  • 30

    Aug

BBT

BB&T

$50.62

-0.47 (-0.92%)

06:03
04/19/18
04/19
06:03
04/19/18
06:03
Earnings
BB&T reports Q1 EPS 94c, consensus 92c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Apr

  • 24

    Apr

GOOG

Alphabet

$1,072.25

-2.17 (-0.20%)

, GOOGL

Alphabet Class A

$1,075.28

-4.12 (-0.38%)

06:02
04/19/18
04/19
06:02
04/19/18
06:02
Periodicals
Google Pay surpasses 100M downloads on Play Store, Android Police says »

Google Pay, called…

GOOG

Alphabet

$1,072.25

-2.17 (-0.20%)

GOOGL

Alphabet Class A

$1,075.28

-4.12 (-0.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 23

    Apr

INTC

Intel

$53.61

0.08 (0.15%)

06:01
04/19/18
04/19
06:01
04/19/18
06:01
Periodicals
Intel plans to shut down New Devices Group, The Information reports »

Intel plans to shut down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADMS

Adamas Pharmaceuticals

$25.86

0.86 (3.44%)

05:59
04/19/18
04/19
05:59
04/19/18
05:59
Hot Stocks
Adamas Pharmaceuticals announces final results from GOCOVRI Phase 3 study »

Adamas Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Apr

  • 25

    Apr

  • 25

    Apr

  • 12

    Jun

TSLA

Tesla

$293.42

5.8 (2.02%)

05:55
04/19/18
04/19
05:55
04/19/18
05:55
Hot Stocks
Tesla batteries delivering power at 662 locations in Puerto Rico, Musk says »

Tesla CEO Elon Musk…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JPM

JPMorgan

$109.31

-0.9 (-0.82%)

05:55
04/19/18
04/19
05:55
04/19/18
05:55
Hot Stocks
JPMorgan Chase announces branch expansion in Greater Washington DC »

JPMorgan Chase announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

  • 30

    May

  • 13

    Jul

  • 12

    Oct

ICLK

iClick Interactive Asia

$7.76

0.19 (2.51%)

05:55
04/19/18
04/19
05:55
04/19/18
05:55
Conference/Events
iClick Interactive Asia management to meet with Roth Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Apr

  • 20

    Apr

SBNY

Signature Bank

$135.08

-1.99 (-1.45%)

05:52
04/19/18
04/19
05:52
04/19/18
05:52
Hot Stocks
Signature Bank reports Q1 EPS ex-items $2.69, consensus $2.67 »

Reports Q1 book value per…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Apr

  • 25

    Apr

SCCO

Southern Copper

$57.33

0.745 (1.32%)

05:50
04/19/18
04/19
05:50
04/19/18
05:50
Downgrade
Southern Copper rating change  »

Southern Copper…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

FOXA

21st Century Fox

$37.32

-0.22 (-0.59%)

, DIS

Disney

$101.21

-1 (-0.98%)

05:49
04/19/18
04/19
05:49
04/19/18
05:49
Hot Stocks
21st Century Fox rejected rival bid of $34.41 per share for assets »

Disney (DIS) disclosed…

FOXA

21st Century Fox

$37.32

-0.22 (-0.59%)

DIS

Disney

$101.21

-1 (-0.98%)

CMCSA

Comcast

$33.28

0.02 (0.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 08

    May

  • 09

    May

NTRS

Northern Trust

$106.38

-0.04 (-0.04%)

05:47
04/19/18
04/19
05:47
04/19/18
05:47
Hot Stocks
Northern Trust enters partnership with The Northern Pool »

The Northern Pool has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$81.72

-0.09 (-0.11%)

, AMGN

Amgen

$175.14

0.19 (0.11%)

05:36
04/19/18
04/19
05:36
04/19/18
05:36
Hot Stocks
Novartis appoints John Tsai as Chief Medical Officer, Head of GDD »

Novartis (NVS) announced…

NVS

Novartis

$81.72

-0.09 (-0.11%)

AMGN

Amgen

$175.14

0.19 (0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 24

    Apr

  • 30

    Apr

  • 17

    May

  • 21

    May

  • 28

    May

  • 05

    Jun

AMZN

Amazon.com

$1,527.24

23.92 (1.59%)

05:36
04/19/18
04/19
05:36
04/19/18
05:36
Recommendations
Amazon.com analyst commentary  »

Amazon online retail…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

NVS

Novartis

$81.72

-0.09 (-0.11%)

05:34
04/19/18
04/19
05:34
04/19/18
05:34
Earnings
Novartis confirms FY18 revenue guidance of growth of low to mid single-digit »

Novartis noted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 17

    May

  • 21

    May

  • 05

    Jun

NVS

Novartis

$81.72

-0.09 (-0.11%)

05:34
04/19/18
04/19
05:34
04/19/18
05:34
Hot Stocks
Novartis reports Q1 Alcon sales of $1.8B »

Alcon net sales were…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 17

    May

  • 21

    May

  • 05

    Jun

RDN

Radian Group

$15.36

-0.91 (-5.59%)

05:30
04/19/18
04/19
05:30
04/19/18
05:30
Recommendations
Radian Group analyst commentary  »

Radian Group price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

NVS

Novartis

$81.72

-0.09 (-0.11%)

05:29
04/19/18
04/19
05:29
04/19/18
05:29
Hot Stocks
Novartis Q1 results continue to demonstrate benefit from turnaround plan actions »

Novartis noted, Q1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 17

    May

  • 21

    May

  • 05

    Jun

MTG

MGIC Investment

$10.50

-0.275 (-2.55%)

05:29
04/19/18
04/19
05:29
04/19/18
05:29
Downgrade
MGIC Investment rating change  »

MGIC Investment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESNT

Essent Group

$34.83

-2.045 (-5.55%)

, MTG

MGIC Investment

$10.50

-0.275 (-2.55%)

05:28
04/19/18
04/19
05:28
04/19/18
05:28
Downgrade
Essent Group, MGIC Investment, Radian Group rating change  »

Essent Group downgraded…

ESNT

Essent Group

$34.83

-2.045 (-5.55%)

MTG

MGIC Investment

$10.50

-0.275 (-2.55%)

RDN

Radian Group

$15.36

-0.91 (-5.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 04

    May

NVS

Novartis

$81.72

-0.09 (-0.11%)

05:27
04/19/18
04/19
05:27
04/19/18
05:27
Hot Stocks
Novartis reports Q1 Sandoz net sales of $2.5B »

Sandoz net sales were…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 17

    May

  • 21

    May

  • 05

    Jun

NVS

Novartis

$81.72

-0.09 (-0.11%)

05:25
04/19/18
04/19
05:25
04/19/18
05:25
Earnings
Novartis reports Q1 core EPS $1.28, consensus $1.29 »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 17

    May

  • 21

    May

  • 05

    Jun

PG

Procter & Gamble

$78.19

-0.23 (-0.29%)

, TEVA

Teva

$17.91

0.065 (0.36%)

05:23
04/19/18
04/19
05:23
04/19/18
05:23
Hot Stocks
Procter & Gamble acquires Consumer Health business of Merck KGaA for EUR 3.4B »

Procter & Gamble (PG)…

PG

Procter & Gamble

$78.19

-0.23 (-0.29%)

TEVA

Teva

$17.91

0.065 (0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Apr

  • 27

    Apr

  • 18

    May

  • 05

    Jun

  • 16

    Jun

GOL

GOL Linhas

$13.51

0.72 (5.63%)

05:22
04/19/18
04/19
05:22
04/19/18
05:22
Downgrade
GOL Linhas rating change  »

GOL Linhas downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.